Jing Ji Guan Cha Wang·2026-02-21 03:27Core Insights - The company expects a significant increase in net profit for 2025, projecting a year-on-year growth of 105% to 204%, while the non-deductible net profit is anticipated to decline by 43% to 61%, primarily driven by non-recurring gains such as financial asset investment income [1][2] Financial Performance - The company forecasts a net addition of orders between 9.5 billion to 10.5 billion yuan for 2025, reflecting a year-on-year growth of 13% to 25%, indicating a recovery in demand [3] - Operating cash flow is expected to reach 1.1 billion to 1.3 billion yuan for 2025, showing a slight increase compared to the previous year [5] Business Development - The company acquired a 56.37% stake in MICRON for 23.48 million yuan through its Japanese subsidiary, aiming to expand its overseas business in medical imaging evaluation [4] - The company has established a presence in 33 countries, with 150 international multi-center clinical trial projects, highlighting its global strategy [4] Industry Context - The clinical CRO industry is recovering alongside the rebound in financing for innovative drugs, with the company maintaining a leading position in the Chinese clinical CRO market [5] - The management indicated that multinational pharmaceutical companies may increase clinical trials in China, with an expectation of accelerated order conversion in the first half of 2026 [3]